about
NANOS1 and PUMILIO2 bind microRNA biogenesis factor GEMIN3, within chromatoid body in human germ cellsEpigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancerNetwork-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer RiskUnsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival.Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer TypesPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSNo Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.Assessing the genetic architecture of epithelial ovarian cancer histological subtypes.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.Limited clinical relevance of mitochondrial DNA mutation and gene expression analyses in ovarian cancer.A novel germline PALB2 deletion in Polish breast and ovarian cancer patientsHAX-1 overexpression, splicing and cellular localization in tumors.Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancerConsortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.Cyclooxygenase-2 immunohistochemical expression in serrated polyps of the colonGermline SMARCA4 mutations in patients with ovarian small cell carcinoma of hypercalcemic type.Identification of six new susceptibility loci for invasive epithelial ovarian cancer.The Novel Gene CRNDE Encodes a Nuclear Peptide (CRNDEP) Which Is Overexpressed in Highly Proliferating Tissues.Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) RiskCis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancerShared genetics underlying epidemiological association between endometriosis and ovarian cancer.Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancersEpithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) RiskCommon Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC).Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fractionThe putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients.TP53 status determines clinical significance of ERBB2 expression in ovarian cancer.Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome.Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancerEvaluating the ovarian cancer gonadotropin hypothesis: a candidate gene studyBRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian CancersIdentification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.Gene expression analysis in ovarian cancer - faults and hints from DNA microarray study.p19(INK4d) mRNA and protein expression as new prognostic factors in ovarian cancer patients.
P50
Q24317694-EA53532D-AEB2-40EF-9281-3405B3A5B834Q24633316-17D3EF1A-D1B6-45B5-A850-0A9B7E5169F1Q26799669-2742D8F1-832C-4B43-A03E-B50B4DAFFE62Q27320720-4655ABD3-6FBA-43F8-B986-92A1EE55279AQ28388497-258719B6-681F-440C-B7A9-2C1A68979678Q28584533-DFB281C5-C44E-416C-8940-6319FF6D012EQ30275832-2D6BBD1C-E037-4346-8348-CCFBF1D9F0F2Q30276986-8A101D69-7B28-49DF-BEC1-1E33C0FECDAEQ30374367-174620E2-4852-473E-97AC-D9B893DDF582Q33317044-CDCDD864-9709-45A4-AD22-402E06617740Q33374622-A3671C92-5EE5-4862-BFA5-390819753C6BQ33528298-5978A292-31CB-49C6-A255-983FB3EFDAB2Q33536132-BAD4A3F4-792B-4D53-86F6-068096492175Q33778612-FA1EDBF0-917C-44F3-BE6E-912C29D57B7FQ33847791-13202F0B-3D85-46F1-8F26-5F5050D4CA12Q34342248-AFF8A6A5-B4DD-4590-8CB7-53CFB907B817Q35165588-3B298E08-E011-42C8-9354-B4FC256964E1Q35195271-964229A3-FBBE-4781-9BBC-D2B5742736E2Q35541663-058A6209-9745-47DB-8C0D-B1EA663918F1Q35632884-D0B65C14-4139-407F-B88A-ECA465C23EFAQ35668946-429CC07A-AD7C-497D-A096-ACCCB75FCF18Q35782435-A7A1EB2C-C803-466C-9BC9-F02B5F1779D0Q36089391-3D2CC891-E936-42CD-B071-3DD20B74364EQ36124728-182899E9-7E6D-4911-965A-3AC27D3B9F67Q36218993-0DBE7011-134A-4BE3-9A8F-247AA94B51F5Q36255665-002CC859-F8A0-4F65-9FC9-E0A535DB9A60Q36374452-FCC39F71-65AE-4E88-AC0C-14F60C3C1486Q36487146-6C13448E-F8CB-4FBC-ACFB-3195419B44ADQ36490507-7A6AD162-07FE-4929-A70C-F1EF752072D3Q36621208-3B1192EB-E913-4C5A-B408-00C65BF9D7E8Q36685531-AF7DF88E-8646-4C4B-9A2A-7948C2D16AD3Q36695189-3A89DD98-9A63-4D56-9C6D-3098585F2805Q36831854-A075C7B3-D843-4A3F-B5CF-9D8FF5E27E8FQ36897003-D9BBDA6B-14BD-4CF7-9CC4-CDFA021E57BBQ36956156-FF8DD186-14CF-420F-A6BD-EF7AB2D320D6Q36966218-D007FE70-B2F5-49E2-B2FA-9D9381667C14Q37002955-A8C6D494-C578-4DAF-A290-1C2D39DF1AC9Q37006170-726EAD6C-52E6-426E-B1C0-358E743085CDQ37522638-D85C11A7-6CA2-432E-B696-31A44FC8EF7DQ37589242-5571DB73-D025-4273-A6C6-28B53065A624
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jolanta Kupryjanczyk
@ast
Jolanta Kupryjanczyk
@en
Jolanta Kupryjanczyk
@es
Jolanta Kupryjanczyk
@sl
type
label
Jolanta Kupryjanczyk
@ast
Jolanta Kupryjanczyk
@en
Jolanta Kupryjanczyk
@es
Jolanta Kupryjanczyk
@sl
prefLabel
Jolanta Kupryjanczyk
@ast
Jolanta Kupryjanczyk
@en
Jolanta Kupryjanczyk
@es
Jolanta Kupryjanczyk
@sl
P106
P21
P31
P496
0000-0001-5820-0214